GUD vs. THCX, CRON, TLRY, ACB, WEED, FIRE, EPI, ICC, RIV, and CPH
Should you be buying Knight Therapeutics stock or one of its competitors? The main competitors of Knight Therapeutics include Hydropothecary (THCX), Cronos Group (CRON), Tilray Brands (TLRY), Aurora Cannabis (ACB), Canopy Growth (WEED), Supreme Cannabis (FIRE), ESSA Pharma (EPI), ICC Labs (ICC), RIV Capital (RIV), and Cipher Pharmaceuticals (CPH). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Knight Therapeutics vs.
Knight Therapeutics (TSE:GUD) and Hydropothecary (CVE:THCX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, community ranking, risk and dividends.
Knight Therapeutics currently has a consensus target price of C$7.13, indicating a potential upside of 18.36%. Given Knight Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Knight Therapeutics is more favorable than Hydropothecary.
Hydropothecary has a net margin of 0.00% compared to Knight Therapeutics' net margin of -8.81%. Hydropothecary's return on equity of 0.00% beat Knight Therapeutics' return on equity.
Hydropothecary has lower revenue, but higher earnings than Knight Therapeutics.
12.6% of Knight Therapeutics shares are held by institutional investors. 45.6% of Knight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Hydropothecary received 28 more outperform votes than Knight Therapeutics when rated by MarketBeat users. However, 73.38% of users gave Knight Therapeutics an outperform vote while only 72.31% of users gave Hydropothecary an outperform vote.
In the previous week, Knight Therapeutics had 13 more articles in the media than Hydropothecary. MarketBeat recorded 13 mentions for Knight Therapeutics and 0 mentions for Hydropothecary. Knight Therapeutics' average media sentiment score of 0.42 beat Hydropothecary's score of 0.00 indicating that Knight Therapeutics is being referred to more favorably in the media.
Summary
Knight Therapeutics beats Hydropothecary on 11 of the 14 factors compared between the two stocks.
Get Knight Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Knight Therapeutics Competitors List
Related Companies and Tools
This page (TSE:GUD) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy GUD Stock Free GUD Stock Alerts